Drug Discovery Seminars: Catalyzing Confidence: A Novel Strategy for Enhancing DEL Hit Validation in Drug Discovery Presenter: Dr Stefan Geschwindner, PhD, Director Biophysics, AstraZeneca, Mölndal, Sweden Host: Pauliina Turunen, Unit Target Protein Engineering (TPE), SciLifeLab DDD Abstract In the realm of drug discovery, validating hits derived from DNA-encoded library (DEL) screening is an indispensable step. […]

This presentation will describe this workflow and discuss considerations for various ONT classes, emphasizing the importance of ONT-specific factors such as chemistry, delivery systems, and tissue distribution in OffT evaluation. It will also cover strategies for experimental verification and risk assessment and discuss the potential of machine learning models to enhance OffT prediction.

The seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE, that will train 48 future leaders in life sciences. The program focuses on innovative, fundamental and translational research carried out in supportive and diverse academic and industrial environments, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to […]

This presentation will provide an overview of the selection and screening processes, as well as future challenges for antibody-based drugs. It will be exemplified with data from one of Alligator Bioscience's bispecific antibody drug candidates, ATOR-4066.

This talk traces the evolution of molecular glues, framing them as versatile proximity-inducing agents rather than just degradation tools. I emphasize their impact on our understanding of protein surfaces and cellular organization.

The Seqitope® and Opti-Mab® technologies originated from projects together with SciLifeLab DDD. Seqitope® is a high-resolution epitope mapping platform that combines large-scale wet-lab screening with advanced bioinformatics. By utilizing phage display of libraries containing millions of mutated antigen variants, it goes far beyond classical alanine scanning

This seminar will describe Dr. Lorenz M. Mayr's experience in drug discovery from over 30 years in industry, academia, venture capital/financing and finally running Biotech startup companies. He is driven by his passion for science, interdisciplinary research and impact for patients. The ultimate goal has always been to bring innovative, impactful and affordable medicine to patients.

This seminar describes the BrainTransporterTM (BT) technology for transport of molecules across the blood brain barrier (BBB)